We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Labcorp Stock to Your Portfolio Right Now
Read MoreHide Full Article
Key Takeaways
Labcorp's Biopharma Laboratory Services grew 11% in Q2, led by Central Labs and Early Development.
Operational initiatives like LaunchPad and digital tools are improving LH's margins and efficiencies.
Currency headwinds and macroeconomic pressures continue to challenge Labcorp's growth prospects.
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is well-poised to grow in the coming quarters, courtesy of its Biopharma Laboratory Services (“BLS”) segment’s robust growth. A strong focus on operational efficiency adds to its appeal. Also, robust solvency looks encouraging. Yet, macroeconomic challenges may hinder the company’s full growth potential.
In the past year, this Zacks Rank #2 (Buy) stock has risen 24.1% against a 17.9% decline of the industry. It has also outpaced the S&P 500 composite’s 18.7% growth.
The renowned healthcare diagnostics company has a market capitalization of $23.04 billion. LH has an earnings yield of 5.8% compared with the industry’s 4.2%. Labcorp beat on earnings in each of the trailing four quarters, the average surprise being 2.5%.
Let’s dive deeper.
Tailwinds for Labcorp
BLS Expansion Continues: This business is benefiting from collaborations with leading pharmaceutical and biotechnology companies with whom it started working on potential antivirals, treatments, and vaccines. In the second quarter of 2025, the segment grew 11% year over year, driven by 8% growth in Central Laboratories and a 20% increase in the Early Development business.
Labcorp has already established itself as a key partner to biopharma in CDx, supporting the international expansion of specialized diagnostics. As its pipeline grows, the company aims to leverage its scientific leadership in new markets through a unique set of capabilities, including a global central laboratory footprint and deep customer relationships in diagnostics and biopharma laboratory services.
Focus on Operational Efficiency: Labcorp is focused on enhancing customer and employee experiences and leveraging technology to drive ongoing operational and process efficiencies. In 2021, the company launched its business process improvement initiative, LaunchPad, and supported the 20-basis-point (bps) improvement in the adjusted operating margin in the second quarter.
Furthermore, the company is introducing new operational efficiencies designed to enhance margins. These include the Labcorp Diagnostic Assistant, a digital solution integrated intoelectronic health record that supports providers with real-time access to comprehensive laboratory data, insights and self-service capabilities. Labcorp also launched eClaim Assist, a next-generation digital platform that introduces smarter workflows to improve efficiencies in billing, payer alignment and denials.
Solvency, Buybacks, and Dividends: Labcorp boasts a sound financial health, ending the second quarter of 2025 with cash and cash equivalents of $793 million and short-term debt of $500 million. Long-term debt was $5.08 billion compared with $5.47 billion at the end of the first quarter. The company had a times interest earned ratio of 5.3%, consistent with the previous quarter. Labcorp also returns capital to shareholders through its share repurchase program and dividends. During the quarter, it paid $59.9 million in dividends and repurchased $200.0 million of stock. The dividend payout ratio was 19% at the quarter's end.
Image Source: Zacks Investment Research
Headwind for Labcorp
Macroeconomic Risks: Labcorp’s operations are heavily dependent on the demand for diagnostic testing and drug development services. In recent times, volatilities in global economic conditions, including inflation, have significantly reduced the demand for these services. Furthermore, the escalation of current geopolitical tensions and retaliatory tariffs is putting pressure on the supply chain and services, leading to increased prices for offerings. In the second quarter of 2025, the cost of revenues went up 8.1% year over year. SG&A expenses increased 3.8%.
LH Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2025 earnings has remained unchanged at $16.30.
The Zacks Consensus Estimate for 2025 revenues is pegged at $14.00 billion, suggesting a 7.7% improvement from the 2024 comparable figure.
Other Key Picks
Some other top-ranked stocks in the broader medical space are GE HealthCare Technologies (GEHC - Free Report) , Masimo (MASI - Free Report) and Phibro Animal Health (PAHC - Free Report) .
GE HealthCare has an earnings yield of 5.8% compared with the industry’s 0.2%. Shares of the company have surged 76.5% compared with the industry’s 3.4% growth. GEHC’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 12.5%.
Masimo, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 12.5% compared with the industry’s 9.9%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 9.17%. MASI’s shares have rallied 18.9% against the industry’s 15.4% decline in the past year.
Phibro, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 17.2% for fiscal 2026 compared with the S&P 500 composite’s 10.9%. Shares of the company have rallied 101.1% compared with the industry’s 3% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Add Labcorp Stock to Your Portfolio Right Now
Key Takeaways
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is well-poised to grow in the coming quarters, courtesy of its Biopharma Laboratory Services (“BLS”) segment’s robust growth. A strong focus on operational efficiency adds to its appeal. Also, robust solvency looks encouraging. Yet, macroeconomic challenges may hinder the company’s full growth potential.
In the past year, this Zacks Rank #2 (Buy) stock has risen 24.1% against a 17.9% decline of the industry. It has also outpaced the S&P 500 composite’s 18.7% growth.
The renowned healthcare diagnostics company has a market capitalization of $23.04 billion. LH has an earnings yield of 5.8% compared with the industry’s 4.2%. Labcorp beat on earnings in each of the trailing four quarters, the average surprise being 2.5%.
Let’s dive deeper.
Tailwinds for Labcorp
BLS Expansion Continues: This business is benefiting from collaborations with leading pharmaceutical and biotechnology companies with whom it started working on potential antivirals, treatments, and vaccines. In the second quarter of 2025, the segment grew 11% year over year, driven by 8% growth in Central Laboratories and a 20% increase in the Early Development business.
Labcorp has already established itself as a key partner to biopharma in CDx, supporting the international expansion of specialized diagnostics. As its pipeline grows, the company aims to leverage its scientific leadership in new markets through a unique set of capabilities, including a global central laboratory footprint and deep customer relationships in diagnostics and biopharma laboratory services.
Focus on Operational Efficiency: Labcorp is focused on enhancing customer and employee experiences and leveraging technology to drive ongoing operational and process efficiencies. In 2021, the company launched its business process improvement initiative, LaunchPad, and supported the 20-basis-point (bps) improvement in the adjusted operating margin in the second quarter.
Furthermore, the company is introducing new operational efficiencies designed to enhance margins. These include the Labcorp Diagnostic Assistant, a digital solution integrated intoelectronic health record that supports providers with real-time access to comprehensive laboratory data, insights and self-service capabilities. Labcorp also launched eClaim Assist, a next-generation digital platform that introduces smarter workflows to improve efficiencies in billing, payer alignment and denials.
Solvency, Buybacks, and Dividends: Labcorp boasts a sound financial health, ending the second quarter of 2025 with cash and cash equivalents of $793 million and short-term debt of $500 million. Long-term debt was $5.08 billion compared with $5.47 billion at the end of the first quarter. The company had a times interest earned ratio of 5.3%, consistent with the previous quarter. Labcorp also returns capital to shareholders through its share repurchase program and dividends. During the quarter, it paid $59.9 million in dividends and repurchased $200.0 million of stock. The dividend payout ratio was 19% at the quarter's end.
Image Source: Zacks Investment Research
Headwind for Labcorp
Macroeconomic Risks: Labcorp’s operations are heavily dependent on the demand for diagnostic testing and drug development services. In recent times, volatilities in global economic conditions, including inflation, have significantly reduced the demand for these services. Furthermore, the escalation of current geopolitical tensions and retaliatory tariffs is putting pressure on the supply chain and services, leading to increased prices for offerings. In the second quarter of 2025, the cost of revenues went up 8.1% year over year. SG&A expenses increased 3.8%.
LH Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2025 earnings has remained unchanged at $16.30.
The Zacks Consensus Estimate for 2025 revenues is pegged at $14.00 billion, suggesting a 7.7% improvement from the 2024 comparable figure.
Other Key Picks
Some other top-ranked stocks in the broader medical space are GE HealthCare Technologies (GEHC - Free Report) , Masimo (MASI - Free Report) and Phibro Animal Health (PAHC - Free Report) .
GE HealthCare has an earnings yield of 5.8% compared with the industry’s 0.2%. Shares of the company have surged 76.5% compared with the industry’s 3.4% growth. GEHC’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 12.5%.
GEHC carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 12.5% compared with the industry’s 9.9%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 9.17%. MASI’s shares have rallied 18.9% against the industry’s 15.4% decline in the past year.
Phibro, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 17.2% for fiscal 2026 compared with the S&P 500 composite’s 10.9%. Shares of the company have rallied 101.1% compared with the industry’s 3% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%.